Considerations for the use of immunosuppression for the management of pemphigus during the COVID-19 pandemic with a focus on rituximab: Case reports from a single center experience in Australia

Review Medicine, General & Internal

Autoimmune bullous diseases during COVID-19 pandemic: 2022 update on rituximab and vaccine

Anna Pira et al.

Summary: Autoimmune bullous diseases (AIBDs) are life-threatening disorders associated with blistering. The COVID-19 pandemic has had a heavy impact on AIBD patients, who are considered fragile due to their increased risk of infections.

FRONTIERS IN MEDICINE (2023)

添加到收藏夹

Article Health Policy & Services

Australia's Response to COVID-19

Anika Stobart et al.

Summary: This paper describes Australia's experience in combating the COVID-19 pandemic in 2020 and the first half of 2021. While Australia successfully eliminated community transmission, its slow vaccination program has left it lagging behind other countries in terms of vaccine rollout.

HEALTH ECONOMICS POLICY AND LAW (2022)

添加到收藏夹

Letter Dermatology

Incidence and severity of COVID-19 in patients with autoimmune blistering skin diseases: A nationwide study

Pascal Joly et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2022)

添加到收藏夹

Article Dermatology

Can rituximab be used in the treatment of pemphigus vulgaris during the COVID-19 pandemic?

Tugba Kevser Uzuncakmak et al.

Summary: The study found that pemphigus patients who have received rituximab treatment within the previous 5 years have a lower risk of COVID-19 infection, regardless of the number of treatment courses or the duration since treatment. The disease course was mild in the only infected patient, suggesting that rituximab may be used for pemphigus treatment during the COVID-19 pandemic if necessary.

DERMATOLOGIC THERAPY (2021)

添加到收藏夹

Letter Dermatology

Characteristics and outcomes of COVID-19 in patients with autoimmune bullous diseases: A retrospective cohort study

Hamidreza Mahmoudi et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)

添加到收藏夹

Article Rheumatology

Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry

Anja Strangfeld et al.

Summary: Factors associated with COVID-19-related death in people with rheumatic diseases include age, sex, comorbidities, disease activity, and specific medications. Adequate disease control with disease-modifying anti-rheumatic drugs (DMARDs) without increasing glucocorticoid dosages is important, while caution may be required with certain medications such as rituximab and sulfasalazine.

ANNALS OF THE RHEUMATIC DISEASES (2021)

添加到收藏夹

Article Rheumatology

Biological agents for rheumatic diseases in the outbreak of COVID-19: friend or foe?

Cristiana Sieiro Santos et al.

Summary: The study found that patients treated with biological agents have a lower risk of contracting COVID-19 and can still be managed at home during the outbreak, while IL-6 inhibitors may have a protective effect.

RMD OPEN (2021)

添加到收藏夹

Letter Dermatology